Wei Li

Use of the WHO Access, Watch, and Reserve classification to define patterns of hospital antibiotic use (AWaRe): an analysis of paediatric survey data from 56 countries

Yingfen Hsia, Brian Lee, Ann Versporten et al. · The Lancet Global Health · 2019 · 352 citations · Full text

Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial

Yuankai Shi, Hang Su, Yongping Song et al. · The Lancet Haematology · 2019 · 233 citations

Lymphoid Neoplasia, Medicine, Immunotherapy +2

Low-Molecular-Weight Peptides Derived from Extracellular Matrix as Chemoattractants for Primary Endothelial Cells

Fankang Li, Wei Li, Scott A. Johnson et al. · Endothelium · 2004 · 199 citations

Tissue Engineering, Engineering, Immunology +24

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada et al. · The Lancet Oncology · 2018 · 152 citations · Full text

Lymphoid Neoplasia, End-of-induction Pet Response, Medicine +7

Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial

Matthew J. Matasar, Marcelo Capra, Muhıt Özcan et al. · The Lancet Oncology · 2021 · 132 citations · Full text

Lymphoid Neoplasia, Medicine, Pharmacology +7